

Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study


Background

Dr. Sean Glenn, Roswell Park Cancer Institute, shares his insights using the SureSeq™ Myeloid MRD Plus NGS Panel in a retrospective cohort study of research specimens collected from patients undergoing AML treatment to assess MRD signals as compared to Bone Marrow Morphology (BMM) and Flow Cytometry (FCM)


Key takeaways

A targeted NGS panel that fits your samples...

73% of bone-marrow transplant AML samples in the study had at least 1 mutation detected by the **SureSeq Myeloid MRD Plus NGS Panel**



Percentage of unique AML samples with at least 1 mutation detectable by the SureSeq Myeloid MRD Plus NGS Panel



...with superior sensitivity

The **SureSeq Myeloid MRD Plus NGS Panel** showed superior sensitivity with earlier MRD signal detection compared to BMM and FCM

...so you can detect MRD signals sooner

The **SureSeq Myeloid MRD Plus NGS Panel** median lead time for MRD signal detection was ~82 days compared to FCM



A Sysmex Group Company